No Data
No Data
Kanghui Pharmaceutical 2024 Semi-Annual Report
Summary of Kanghui Pharmaceutical\'s 2024 Semi-Annual Report
Shaanxi Kanghui Pharmaceutical (603139.SH): net loss of 8.702 million yuan in the first half of the year.
On August 29th, Kanghui Pharmaceutical (603139.SH) announced its 2024 interim report, achieving operating revenue of 0.266 billion yuan in the first half of the year, a year-on-year decrease of 1.35%; achieving a net income attributable to shareholders of the listed company of -8.702 million yuan.
Shaanxi Kanghui Pharmaceutical (603139.SH) announced its performance for the first half of the year, with a net loss of 8.702 million yuan, shifting from profit to loss.
Shaanxi Kanghui Pharmaceutical (603139.SH) released the semi-annual report for 2024, with a revenue of 0.266 billion yuan,...
Shaanxi Kanghui Pharmaceutical (603139.SH): Currently no drugs to treat acne virus.
On August 20th, Gelunhui reported that Shaanxi Kanghui Pharmaceutical (603139.SH) currently does not have any drugs to treat acne viruses on the investor interaction platform.
Kanghui Pharmaceutical's Shaanxi Production Base Renews Production License; Shares Down 6%
No Data
No Data